February 22, 2022
A New Jersey federal judge adopted a special master's report Tuesday approving two settlements totaling over $23 million to resolve claims that the former Valeant Pharmaceuticals used a "secret network of captive pharmacies" to stifle generic competition, driving up prices for third-party payors.
August 06, 2021
Valeant Pharmaceuticals agreed Thursday to pay $23 million to end a proposed class action accusing the drug company of violating the Racketeer Influenced and Corrupt Organizations Act with an alleged scheme to block its drugs from generic competition through a "secret network of captive pharmacies."
May 31, 2016
Valeant Pharmaceuticals International Inc. was hit Friday with a proposed class action accusing the drug company and its executives of violating the Racketeer Influenced and Corrupt Organizations Act with an alleged scheme to block the company's drugs from competition through a "secret network of captive pharmacies."